GeneDx Holdings (WGS) Total Non-Current Liabilities (2020 - 2026)

GeneDx Holdings (WGS) has reported Total Non-Current Liabilities for 7 consecutive years, with $252.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 38.21% year-over-year to $252.1 million; the TTM figure through Mar 2026 stood at $252.1 million (up 38.21% YoY), while the FY2025 annual figure was $213.9 million, up 26.85% from the prior year.
• Total Non-Current Liabilities climbed to $252.1 million in Q1 2026 per WGS's latest filing, from $213.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $295.5 million in Q2 2022 and bottomed at $140.4 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $196.9 million across 5 years, with a median of $184.8 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 51.89% — and 2026, when it soared 38.21%.
• GeneDx Holdings' Total Non-Current Liabilities stood at $213.2 million in 2022, then slipped by 17.45% to $176.0 million in 2023, then fell by 4.2% to $168.6 million in 2024, then grew by 26.85% to $213.9 million in 2025, then climbed by 17.87% to $252.1 million in 2026.
• Business Quant data shows WGS's Total Non-Current Liabilities at $252.1 million in Q1 2026, $213.9 million in Q4 2025, and $197.4 million in Q3 2025.